fMRI Neurofeedback With Matter Neuroscience App
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorStanford University
About this trial
Study will utilize an app, Matter Neuroscience, designed to help users with depression understand positive emotions and the neurotransmitters that create them. We hope to learn the safety and efficacy of neurofeedback for treating depression and lay the groundwork for a pivotal clinical trial.
Eligibility criteria
Qualifiers
Male or Female, between the ages of 18 and 80 at the time of screening.
Primary diagnosis of nonpsychotic major depressive disorder (MDD) without a history of psychotic features.
Score on the MADRS scale between 15-25
Able to read, understand, and provide written, dated informed consent prior to screening. Proficiency in English sufficient to complete questionnaires / follow instructions during fMRI. Stated willingness to comply with all study procedures, including availability for the duration of the study, and to communicate with study personnel about adverse events and other clinically important information.
Disqualifiers
Contraindication to MRI (ferromagnetic metal in their body)
Severe claustrophobia
Women that are pregnant or breastfeeding or with a positive urine pregnancy test at participation, or who are planning to become pregnant during the study period.
Primary psychiatric condition other than MDD requiring treatment except stable comorbid anxiety disorder
Trial design
Treatments tested in this trial
- Matter Neuroscience App
- Stock Photos
- No Home Training
- Personal Photos
- Home Training
Treatment groups
240 Participants
are divided into 8 treatment groups8
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov